Cargando…

Efficacy of Perioperative Continuous Intravenous Lidocaine Infusion for 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: Study Protocol for a Prospective Randomized Controlled Trial

PURPOSE: Many patients develop severe and persistent pain after hepatectomy delaying postoperative rehabilitation. Studies have suggested that intravenous lidocaine infusion relieved postoperative pain and improved overall postoperative outcomes. However, its efficacy on hepatectomy is still masked,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yan, Ye, Mao, Hong, Ying, Kang, Yi, Li, Yue, Xiao, Xiao, Zhou, Li, Jiang, Chunling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646227/
https://www.ncbi.nlm.nih.gov/pubmed/34880671
http://dx.doi.org/10.2147/JPR.S341550
_version_ 1784610479436464128
author Xu, Yan
Ye, Mao
Hong, Ying
Kang, Yi
Li, Yue
Xiao, Xiao
Zhou, Li
Jiang, Chunling
author_facet Xu, Yan
Ye, Mao
Hong, Ying
Kang, Yi
Li, Yue
Xiao, Xiao
Zhou, Li
Jiang, Chunling
author_sort Xu, Yan
collection PubMed
description PURPOSE: Many patients develop severe and persistent pain after hepatectomy delaying postoperative rehabilitation. Studies have suggested that intravenous lidocaine infusion relieved postoperative pain and improved overall postoperative outcomes. However, its efficacy on hepatectomy is still masked, due to the postoperative metabolic change of lidocaine by the liver. We hypothesized that intravenous lidocaine infusion in the perioperative period would lead to postoperative pain reduction and improve the overall patient experience. STUDY DESIGN AND METHODS: In this prospective double-blind, randomized controlled design trial, 260 adults scheduled for hepatectomy will be allocated to the lidocaine and the placebo groups. The lidocaine group will be administered lidocaine intravenously during intraoperative period and 72 postoperative hours; the placebo group will be administered normal saline at the same volume, infusion rate, and timing. The primary outcome is the incidence of moderate-severe pain (numeric rating scale ≥4) during movement at 24 hours after surgery. The secondary outcomes include the incidence of moderate-severe pain at 24 hours after surgery at rest, the incidence of moderate-severe pain at 48 and 72 hours after surgery at rest and during movement, the cumulative morphine consumption at 24, 48 and 72 hours postoperatively, bowel function recovery, the incidence of postoperative nausea and vomiting, the incidence of postoperative pulmonary complications, the length of hospital stay, levels of inflammatory factors and patient satisfaction scores. DISCUSSION: This is the first prospective trial to shed light on the efficacy of intraoperative period and 72 postoperative hours intravenous lidocaine on postoperative pain and recovery after hepatectomy. The findings will provide a new strategy of perioperative pain management for hepatectomy.
format Online
Article
Text
id pubmed-8646227
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86462272021-12-07 Efficacy of Perioperative Continuous Intravenous Lidocaine Infusion for 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: Study Protocol for a Prospective Randomized Controlled Trial Xu, Yan Ye, Mao Hong, Ying Kang, Yi Li, Yue Xiao, Xiao Zhou, Li Jiang, Chunling J Pain Res Study Protocol PURPOSE: Many patients develop severe and persistent pain after hepatectomy delaying postoperative rehabilitation. Studies have suggested that intravenous lidocaine infusion relieved postoperative pain and improved overall postoperative outcomes. However, its efficacy on hepatectomy is still masked, due to the postoperative metabolic change of lidocaine by the liver. We hypothesized that intravenous lidocaine infusion in the perioperative period would lead to postoperative pain reduction and improve the overall patient experience. STUDY DESIGN AND METHODS: In this prospective double-blind, randomized controlled design trial, 260 adults scheduled for hepatectomy will be allocated to the lidocaine and the placebo groups. The lidocaine group will be administered lidocaine intravenously during intraoperative period and 72 postoperative hours; the placebo group will be administered normal saline at the same volume, infusion rate, and timing. The primary outcome is the incidence of moderate-severe pain (numeric rating scale ≥4) during movement at 24 hours after surgery. The secondary outcomes include the incidence of moderate-severe pain at 24 hours after surgery at rest, the incidence of moderate-severe pain at 48 and 72 hours after surgery at rest and during movement, the cumulative morphine consumption at 24, 48 and 72 hours postoperatively, bowel function recovery, the incidence of postoperative nausea and vomiting, the incidence of postoperative pulmonary complications, the length of hospital stay, levels of inflammatory factors and patient satisfaction scores. DISCUSSION: This is the first prospective trial to shed light on the efficacy of intraoperative period and 72 postoperative hours intravenous lidocaine on postoperative pain and recovery after hepatectomy. The findings will provide a new strategy of perioperative pain management for hepatectomy. Dove 2021-12-01 /pmc/articles/PMC8646227/ /pubmed/34880671 http://dx.doi.org/10.2147/JPR.S341550 Text en © 2021 Xu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Study Protocol
Xu, Yan
Ye, Mao
Hong, Ying
Kang, Yi
Li, Yue
Xiao, Xiao
Zhou, Li
Jiang, Chunling
Efficacy of Perioperative Continuous Intravenous Lidocaine Infusion for 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: Study Protocol for a Prospective Randomized Controlled Trial
title Efficacy of Perioperative Continuous Intravenous Lidocaine Infusion for 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: Study Protocol for a Prospective Randomized Controlled Trial
title_full Efficacy of Perioperative Continuous Intravenous Lidocaine Infusion for 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: Study Protocol for a Prospective Randomized Controlled Trial
title_fullStr Efficacy of Perioperative Continuous Intravenous Lidocaine Infusion for 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: Study Protocol for a Prospective Randomized Controlled Trial
title_full_unstemmed Efficacy of Perioperative Continuous Intravenous Lidocaine Infusion for 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: Study Protocol for a Prospective Randomized Controlled Trial
title_short Efficacy of Perioperative Continuous Intravenous Lidocaine Infusion for 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: Study Protocol for a Prospective Randomized Controlled Trial
title_sort efficacy of perioperative continuous intravenous lidocaine infusion for 72 hours on postoperative pain and recovery in patients undergoing hepatectomy: study protocol for a prospective randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646227/
https://www.ncbi.nlm.nih.gov/pubmed/34880671
http://dx.doi.org/10.2147/JPR.S341550
work_keys_str_mv AT xuyan efficacyofperioperativecontinuousintravenouslidocaineinfusionfor72hoursonpostoperativepainandrecoveryinpatientsundergoinghepatectomystudyprotocolforaprospectiverandomizedcontrolledtrial
AT yemao efficacyofperioperativecontinuousintravenouslidocaineinfusionfor72hoursonpostoperativepainandrecoveryinpatientsundergoinghepatectomystudyprotocolforaprospectiverandomizedcontrolledtrial
AT hongying efficacyofperioperativecontinuousintravenouslidocaineinfusionfor72hoursonpostoperativepainandrecoveryinpatientsundergoinghepatectomystudyprotocolforaprospectiverandomizedcontrolledtrial
AT kangyi efficacyofperioperativecontinuousintravenouslidocaineinfusionfor72hoursonpostoperativepainandrecoveryinpatientsundergoinghepatectomystudyprotocolforaprospectiverandomizedcontrolledtrial
AT liyue efficacyofperioperativecontinuousintravenouslidocaineinfusionfor72hoursonpostoperativepainandrecoveryinpatientsundergoinghepatectomystudyprotocolforaprospectiverandomizedcontrolledtrial
AT xiaoxiao efficacyofperioperativecontinuousintravenouslidocaineinfusionfor72hoursonpostoperativepainandrecoveryinpatientsundergoinghepatectomystudyprotocolforaprospectiverandomizedcontrolledtrial
AT zhouli efficacyofperioperativecontinuousintravenouslidocaineinfusionfor72hoursonpostoperativepainandrecoveryinpatientsundergoinghepatectomystudyprotocolforaprospectiverandomizedcontrolledtrial
AT jiangchunling efficacyofperioperativecontinuousintravenouslidocaineinfusionfor72hoursonpostoperativepainandrecoveryinpatientsundergoinghepatectomystudyprotocolforaprospectiverandomizedcontrolledtrial